VERV vs. JANX, AMRX, RCKT, DCPH, BHC, MRVI, CPRX, AMPH, SNDX, and EWTX
Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Janux Therapeutics (JANX), Amneal Pharmaceuticals (AMRX), Rocket Pharmaceuticals (RCKT), Deciphera Pharmaceuticals (DCPH), Bausch Health Companies (BHC), Maravai LifeSciences (MRVI), Catalyst Pharmaceuticals (CPRX), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical preparations" industry.
Janux Therapeutics (NASDAQ:JANX) and Verve Therapeutics (NASDAQ:VERV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.
Janux Therapeutics has a beta of 3.58, meaning that its share price is 258% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.
In the previous week, Janux Therapeutics and Janux Therapeutics both had 6 articles in the media. Verve Therapeutics' average media sentiment score of 0.92 beat Janux Therapeutics' score of 0.13 indicating that Janux Therapeutics is being referred to more favorably in the media.
Janux Therapeutics has higher earnings, but lower revenue than Verve Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Janux Therapeutics has a net margin of -762.92% compared to Janux Therapeutics' net margin of -1,226.51%. Verve Therapeutics' return on equity of -13.49% beat Janux Therapeutics' return on equity.
Janux Therapeutics presently has a consensus price target of $66.29, suggesting a potential upside of 50.68%. Verve Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 345.95%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Verve Therapeutics is more favorable than Janux Therapeutics.
75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 35.4% of Janux Therapeutics shares are held by insiders. Comparatively, 19.3% of Verve Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Janux Therapeutics received 5 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 60.53% of users gave Janux Therapeutics an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.
Summary
Janux Therapeutics beats Verve Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Verve Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verve Therapeutics Competitors List
Related Companies and Tools
